Telix reports a $38 million after-tax profit; FY revenue and other income expected above $1 billion
Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, with gross margin at 55%. Adjusted EBITDA rose 146% to $52M, driven by Precision Medicine sales and a $40M Regeneron collaboration payment. Profit after tax was $38M, reversing a $2M loss from H1 2025. The company expects FY 2026 revenue to exceed $1B and has established a Nasdaq at-the-market equity facility.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise expectations for TLX, potentially driving share price higher.
Market read
First‑report earnings with strong growth and guidance make this a high‑value trading catalyst.
What to watch
The $600M convertible bond refinancing increases debt load; investors should monitor leverage.
Background
Telix Pharmaceuticals (NASDAQ: TLX) released its half‑year financial results and updated FY guidance.
Ticker impact
Telix reported H1 2026 revenue of $477M (+22% YoY) and profit after tax of $38M, plus FY guidance above $1B.
Potential short-term rally of 5-8% as investors price in higher revenue outlook.
First‑report earnings with solid top‑line growth, margin expansion, and new guidance exceed prior expectations.
Market effects
Biotech and precision‑medicine sector may see broader optimism on late‑stage pipeline progress.
Positive for Australian biotech listings and US‑listed biotech ETFs.
Adds to global biotech earnings momentum, supporting risk‑on sentiment.
Counterpoint
Dilution risk from the ATM facility and higher R&D spend could pressure margins if pipeline stalls.
Key entities
- companyTelix Pharmaceuticals
Biotech firm reporting H1 2026 results.
- partnerRegeneron
Provided a $40M upfront payment under collaboration.
